Spinal Cord Compression in Maroteaux-Lamy Syndrome: Case Report and Review of the Literature with Effects of Enzyme Replacement Therapy

The purpose of this report is to review the literature regarding spinal cord compression in mucopolysaccharidosis type VI (MPS VI), to discuss the possible impact of enzyme replacement therapy (ERT) and to stress the necessity of timely surgical intervention. A 9.5-year-old female patient with severe MPS VI had been receiving ERT since the age of 7. After 2.5 years of treatment, she developed craniovertebral canal stenosis with spinal cord compression and cervical myelopathy. Conclusions: (1) baseline cervical spine evaluation and regular neurological assessment should be performed in all MPS VI patients, (2) detailed neurological observation should be conducted in patients treated with ERT, especially in the period of improvement in the osteoarticular system, as ERT fails to prevent cervical myelopathy and (3) surgical decompression is required and in order to achieve a satisfying outcome it might be crucial to perform surgery at an early age.

[1]  A. Tylki-Szymańska,et al.  Cardiovascular manifestations of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome). , 2012, International journal of cardiology.

[2]  G. Węgrzyn,et al.  Molecular analysis of mucopolysaccharidosis type VI in Poland, Belarus, Lithuania and Estonia. , 2012, Molecular genetics and metabolism.

[3]  A. Fischman,et al.  CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder , 2012, PloS one.

[4]  A. Tylki-Szymańska,et al.  Musculoskeletal manifestations of mucopolysaccharidosis type VI and effects of enzyme replacement therapy , 2012 .

[5]  Narayana Varhabhatla,et al.  Rising complication rates after intrathecal catheter and pump placement in the pediatric population: analysis of national data between 1997 and 2006. , 2012, Pain physician.

[6]  Joleen T White,et al.  Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats , 2012, Pediatric Research.

[7]  D. Horovitz,et al.  Spinal cord compression in young children with type VI mucopolysaccharidosis. , 2011, Molecular genetics and metabolism.

[8]  N. Khandelwal,et al.  Maroteaux–Lamy Syndrome (Mucopolysaccharidosis VI) Presenting as Familial Myelopathy , 2011, The International journal of neuroscience.

[9]  A. Mogilner,et al.  Intrathecal pumps , 2011, Neurotherapeutics.

[10]  C. Vite,et al.  Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I. , 2010, Molecular genetics and metabolism.

[11]  R. Giugliani,et al.  Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis. , 2010, Molecular genetics and metabolism.

[12]  J. Finnie,et al.  Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen. , 2010, Molecular genetics and metabolism.

[13]  Agnes H. Chen,et al.  Intrathecal enzyme replacement therapy to treat spinal cord compression in mucopolysaccharidosis: Overview and rationale. , 2010, Journal of pediatric rehabilitation medicine.

[14]  Zi-Fan Yu,et al.  Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase , 2010, Journal of Inherited Metabolic Disease.

[15]  R. Giugliani,et al.  Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression , 2008, American journal of medical genetics. Part A.

[16]  B. Ceulemans,et al.  Opisthotonus and intrathecal treatment with baclofen (ITB) in children , 2008, European Journal of Pediatrics.

[17]  J. Wittes,et al.  Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. , 2006, The Journal of pediatrics.

[18]  R. Giugliani,et al.  Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase , 2005, Pediatrics.

[19]  M. Mut,et al.  Multilevel myelopathy in Maroteaux–Lamy syndrome and review of the literature , 2005, Clinical Neurology and Neurosurgery.

[20]  A. Marzoli,et al.  Mucopolysaccharidosis: thickening of dura mater at the craniocervical junction and other CT/MRI findings , 2005, Pediatric Radiology.

[21]  W. Mobley,et al.  Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. , 2004, Molecular genetics and metabolism.

[22]  P. Kaplan,et al.  Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). , 2004, The Journal of pediatrics.

[23]  M. Javadpour,et al.  Craniovertebral Abnormalities in Type VI Mucopolysaccharidosis (Maroteaux-Lamy Syndrome) , 2001, Neurosurgery.

[24]  R. Del Maestro,et al.  Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation. , 2000, Neurosurgery.

[25]  U. Stephani,et al.  Threatening spinal cord compression during anesthesia in a child with mucopolysaccharidosis VI. , 1994, Anesthesiology.

[26]  N. Tamaki,et al.  Myelopathy due to diffuse thickening of the cervical dura mater in Maroteaux-Lamy syndrome: report of a case. , 1987, Neurosurgery.

[27]  S. Wald,et al.  Compressive myelopathy associated with type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome). , 1984, Neurosurgery.

[28]  R. Ojemann,et al.  Compressive myelopathy in maroteaux‐lamy syndrome: Clinical and pathological findings , 1980, Annals of neurology.

[29]  H. Goebel,et al.  Deficiency of arylsulfatase B in 2 brothers aged 40 and 38 years. (Maroteaux‐Lamy syndrome, type B) , 1979, Annals of neurology.

[30]  H. Bacchus,et al.  Myelopathy associated with Maroteaux-Lamy syndrome. , 1975, Archives of neurology.

[31]  R. Giugliani,et al.  The mucopolysaccharidoses. , 1976, Journal of medical genetics.